Skip to main content

Health policies should incorporate public health priorities

In a letter published in the British Medical Journal (BMJ), Michale Soljak, Chris Millett and I discuss the call by Krogsbøll to abandon the NHS Health Check Programme.As members of one of the research teams evaluating the national programme, we challenge their view that a randomised controlled trial (RCT) of the current programme should be the sole arbiter on which to base national health policy decisions. As noted in comments on the Cochrane review, the dearth of RCTs of screening for cardiovascular (CVD) risk since 1999 is unfortunate, but there were many RCTs of individual screening components over this period that have been used in subsequent NICE guidance.

There are other reasons why Krogsbøll et al’s views should be challenged. Firstly, RCTs are expensive and time-consuming, and as a result, a lack of evidence from RCTs may deprive millions of people of potential benefits from interventions.  RCTs should therefore be complemented where possible by well-validated modelling studies. Screening for CVD risk in six European countries has been evaluated using the Archimedes simulation model, which has been extensively validated against many RCTs. The cost per quality adjusted life year of a universal check was €11,595 in Denmark and €2,426 in the United Kingdom (UK), and if targeted on the top quartile of risk costs would be €1,800 and cost-saving respectively. This is much better societal value than many healthcare interventions, and is very similar to the UK Department of Health’s original health economic impact assessment of the programme.

Secondly, Krogsbøll et al’s conclusion takes no account of the societal costs of waiting for RCT results. A UK analysis of current patterns of statin treatment showed substantial waste and inequity, with overuse in low CVD risk and underuse in high risk (600,000 and 850,000 patients respectively since 2007). There was wide variation between practices in statin prescribing to patients at high CVD risk. Perhaps this is not the case in Denmark, but the UK should not wait for the inverse care law to grind to its eventual outcome. Universal screening programmes  can increase health inequalities if uptake varies, but the Scottish Health Check Programme targets deprived populations as a policy, and in England coverage is significantly higher in PCTs in the most deprived areas. RCTs and Cochrane reviews have little to tell us about health inequalities or the foregone costs and benefits.

Our local early evaluations of the English programme show large increases in appropriate statin prescribing after a Health Check, and significant reductions in mean CVD risk score, diastolic blood pressure, total cholesterol levels and lipid ratios. Uptake is lower than planned, but the equivalent New Zealand programme shows that 75% coverage can be achieved with effective implementation.


Popular posts from this blog

Improving how secondary care and general practice in England work together: the NHS Standard Contract

Due to the increasing pressures on general practices within the National Health Service in England, the interface between primary and secondary care, and the division of labour between these, has become an important issue. This has long been an area prone to difficulties and conflict, the consequences of which can directly impact the quality and safety of patient care, particularly for patients with chronic conditions who regularly transition between these two sectors. In an article published in the Journal of the Royal Society of Medicine, Amy Price and I explore the measures recently implemented in the NHS Standard Contract which aim to target common issues at the primary–secondary care interface, with an aim to reducing inappropriate general practitioner workload in England. We discuss the context behind the implementation of the NHS Standard Contract as well as current concerns and areas for further consideration.

The current crisis in primary care means the NHS Standard Contract…

Patients are more satisfied with general practices managed by GP partners than those managed by companies

General practices in England are independent businesses that are contracted to provide primary care for specified populations. Most are owned by general practitioners, but many types of organisation are now eligible to deliver these services. In a study published in the Journal of the Royal Society of Medicine, we examined the association between patient experience and the contract type of general practices in England, distinguishing limited companies from other practices.

We analysed data from the English General Practice Patient Survey 2013–2014 (July to September 2013 and January to March 2014). Patients were eligible for inclusion in the survey if they had a valid National Health Service number, had been registered with a general practice for six months or more, and were aged 18 years or over. All general practices in England with eligible patients were included in the survey (n = 8017).

Patients registered to general practices owned by limited companies reported worse experience…

Dr Demis Hassabis, Co-Founder and CEO of DeepMind, Speaks about AI in Healthcare

On 28 September 2017, I attended the Annual Institute of Global Health Innovation Lecture: Artificial General Intelligence and Healthcare, delivered by Dr Demis Hassabis, co-founder and CEO of Google DeepMind. Artificial intelligence is the science of making machines smart argued Dr Hassabis, so how can we make it improve the healthcare sector? Dr Hassabis then went on to describe the work that DeepMind was carrying out in healthcare in areas such as organising information, deep learning to support the reporting of medical images (such as scans and pathology slides), and biomedical science. Dr Hassabis also discussed the challenges of applying techniques such as reinforcement learning in healthcare. He concluded that artificial intelligence has great scope for improving healthcare; for example, by prioritising the tasks that clinicians had to carry out and by providing decision support aids for both patients and doctors. Dr Hassabis also discussed some of the ethical issues in using …